Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. (VSTM) on December 15, 2025. The report discloses the departure of a senior executive and related compensatory arrangements effective December 19, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes and associated contractual obligations.
Material Changes
The primary material change is the separation of Matthew Ros from his role as Chief Operating Officer, effective December 19, 2025. A Separation Agreement was executed on the same date.
Guidance, Outlook, and Management Commentary
Management commentary is limited to the terms of the separation. The agreement includes:
- Nine months of base salary continuation.
- Company payment of full COBRA health and dental premiums for nine months (or until new coverage eligibility).
- A pro-rated bonus payment based on the portion of the year employed and actual company performance.
- Customary provisions for release of claims, non-disparagement, cooperation, and return of property.
No forward-looking guidance or financial outlook is provided in this filing.
Investor Verification Checklist
- Verify the exact effective date of the COBRA premium coverage termination.
- Review the specific performance metrics tied to the pro-rated bonus calculation in the full Separation Agreement (Exhibit 10.1).
- Confirm if a replacement Chief Operating Officer has been appointed or if the role is being absorbed by existing management.
- Check subsequent press releases for any impact on ongoing clinical trials or operational strategy.